Korea’s 2nd GIFT drug Nefecon is approved in KOR
By Lee, Hye-Kyung | translator Alice Kang
24.11.22 05:33:38
가나다라
0
recognized for developing a new indication using the already marketed budesonide ingredient
A new drug use to treat primary IgA nephropathy in adults
![](http://pds.dreamdrug.com/newseng_images/202411/6469_1.jpg)
Meditip's Nefecon (budesonide), which was designated as the 2nd Global Innovative Products on Fast Track (GIFT) drug, has been approved in Korea.
The Ministry of Food and Drug Safety approved Nefecon on the 18th.
Nefecon is used to treat primary IgA nephropathy in adults with a urinary protein-to-creatinine ratio of 1.5 or greater who are at risk of rapid progression.
Budesonide, the main ingredient, is already on the market and in use in Korea, but the indication Meditip applied for budesonide's approval as a treatment for new patients who have no existing treatment option, which is why the government designated it as a GIFT drug in March last year.
N
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)